BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36717270)

  • 1. Evaluation of the inhibitory effects of itraconazole on letermovir.
    McCrea JB; Menzel K; Fancourt C; Witter R; Zhao T; Robbins JA; Stoch SA; Iwamoto M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2122-2130. PubMed ID: 36717270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants.
    McCrea JB; Menzel K; Adedoyin A; Cho CR; Fox-Bosetti S; Macha S; Zhao T; Liu F; Panebianco D; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):420-428. PubMed ID: 35157785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
    Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
    J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
    Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
    Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
    J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics
.
    Adedoyin A; Cho CR; Fox-Bosetti S; Macha S; Zhao T; Liu F; Panebianco D; O'Reilly TE; McCrea J; Stoch SA; Iwamoto M
    Int J Clin Pharmacol Ther; 2019 Sep; 57(9):450-457. PubMed ID: 31232280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
    Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
    Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
    J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers.
    Scheuenpflug J; Kropeit D; Erb-Zohar K; Theis JGW; Stobernack HP; McCormick D; Zimmermann H; Rübsamen-Schaeff H
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):6-15. PubMed ID: 34812580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, Metabolism, Distribution, and Excretion of Letermovir.
    Menzel K; Kothare P; McCrea JB; Chu X; Kropeit D
    Curr Drug Metab; 2021; 22(10):784-794. PubMed ID: 33622223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects.
    Kropeit D; McCormick D; Erb-Zohar K; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):16-24. PubMed ID: 34714967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A drug-drug interaction study with letermovir and acyclovir in healthy participants.
    Menzel K; McCrea JB; Fancourt C; Witter R; Zhao T; Stoch SA; Iwamoto M
    Br J Clin Pharmacol; 2023 May; 89(5):1690-1694. PubMed ID: 36537620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
    Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
    Elmeliegy M; Láng I; Smolyarchuk EA; Chung CH; Plotka A; Shi H; Wang D
    Br J Clin Pharmacol; 2020 Apr; 86(4):771-778. PubMed ID: 31770456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.